Top

Published in:

Open Access 01-07-2014 | Review

A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors

Authors: Ingmar Blumcke, Eleonora Aronica, Horst Urbach, Andreas Alexopoulos, Jorge A. Gonzalez-Martinez

Published in: Acta Neuropathologica | Issue 1/2014

Abstract

Every fourth patient submitted to epilepsy surgery suffers from a brain tumor. Microscopically, these neoplasms present with a wide-ranging spectrum of glial or glio-neuronal tumor subtypes. Gangliogliomas (GG) and dysembryoplastic neuroepithelial tumors (DNTs) are the most frequently recognized entities accounting for 65 % of 1,551 tumors collected at the European Epilepsy Brain Bank (n = 5,842 epilepsy surgery samples). These tumors often present with early seizure onset at a mean age of 16.5 years, with 77 % of neoplasms affecting the temporal lobe. Relapse and malignant progression are rare events in this particular group of brain tumors. Surgical resection should be regarded, therefore, also as important treatment strategy to prevent epilepsy progression as well as seizure- and medication-related comorbidities. The characteristic clinical presentation and broad histopathological spectrum of these highly epileptogenic brain tumors will herein be classified as “long-term epilepsy associated tumors—LEATs”. LEATs differ from most other brain tumors by early onset of spontaneous seizures, and conceptually are regarded as developmental tumors to explain their pleomorphic microscopic appearance and frequent association with Focal Cortical Dysplasia Type IIIb. However, the broad neuropathologic spectrum and lack of reliable histopathological signatures make these tumors difficult to classify using the WHO system of brain tumors. As another consequence from poor agreement in published LEAT series, molecular diagnostic data remain ambiguous. Availability of surgical tissue specimens from patients which have been well characterized during their presurgical evaluation should open the possibility to systematically address the origin and epileptogenicity of LEATs, and will be further discussed herein. As a conclusion, the authors propose a novel A–B–C terminology of epileptogenic brain tumors (“epileptomas”) which hopefully promote the discussion between neuropathologists, neurooncologists and epileptologists. It must be our future mission to achieve international consensus for the clinico-pathological classification of LEATs that would also involve World Health Organization (WHO) and the International League against Epilepsy (ILAE).

Alayev A, Holz MK (2013) mTOR signaling for biological control and cancer. J Cell Physiol. doi:10.1002/jcp.24351 PubMed

Arsene D, Ardeleanu C, Ogrezeanu I, Danaila L (2008) Angiocentric glioma: presentation of two cases with dissimilar histology. Clin Neuropathol 27(6):391–395PubMedCrossRef

Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6):597–602. doi:10.1007/s00401-008-0455-2 PubMedCrossRef

Becker AJ, Blumcke I, Urbach H, Hans V, Majores M (2006) Molecular neuropathology of epilepsy-associated glioneuronal malformations. J Neuropathol Exp Neurol 65(2):99–108PubMedCrossRef

Becker AJ, Lobach M, Klein H, Normann S, Nothen MM, von Deimling A, Mizuguchi M, Elger CE, Schramm J, Wiestler OD, Blumcke I (2001) Mutational analysis of TSC1 and TSC2 genes in gangliogliomas. Neuropathol Appl Neurobiol 27(2):105–114PubMedCrossRef

Blumcke I, Becker AJ, Normann S, Hans V, Riederer BM, Krajewski S, Wiestler OD, Reifenberger G (2001) Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and glial precursor cells. J Neuropathol Exp Neurol 60(10):984–993PubMed

Blumcke I, Giencke K, Wardelmann E, Beyenburg S, Kral T, Sarioglu N, Pietsch T, Wolf HK, Schramm J, Elger CE, Wiestler OD (1999) The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies. Acta Neuropathol 97:481–490PubMedCrossRef

Blumcke I, Löbach M, Wolf HK, Wiestler OD (1999) Evidence for developmental precursor lesions in epilepsy-associated glioneuronal tumors. Microsc Res Tech 46(1):53–58PubMedCrossRef

Blumcke I, Luyken C, Urbach H, Schramm J, Wiestler OD (2004) An isomorphic subtype of long-term epilepsy-associated astrocytomas associated with benign prognosis. Acta Neuropathol 107(5):381–388PubMedCrossRef

10.

Blumcke I, Müller S, Buslei R, Riederer BM, Wiestler OD (2004) Microtubule-associated protein-2 immunoreactivity: a useful tool in the differential diagnosis of low-grade neuroepithelial tumors. Acta Neuropathol (Berl) 108(2):89–96

11.

Blumcke I, Thom M, Aronica E, Armstrong DD, Vinters HV, Palmini A, Jacques TS, Avanzini G, Barkovich AJ, Battaglia G, Becker A, Cepeda C, Cendes F, Colombo N, Crino P, Cross JH, Delalande O, Dubeau F, Duncan JS, Guerrini R, Kahane P, Mathern GW, Najm I, Özkara C, Raybaud C, Represa A, Roper SN, Salamon N, Schulze-Bonhage A, Tassi L, Vezzani A, Spreafico R (2011) The clinico-pathological spectrum of Focal Cortical Dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 52(1):158–174PubMedCentralPubMedCrossRef

12.

Blumcke I, Wiestler OD (2002) Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol 61(7):575–584PubMed

13.

Bodi I, Selway R, Bannister P, Doey L, Mullatti N, Elwes R, Honavar M (2012) Diffuse form of dysembryoplastic neuroepithelial tumour: the histological and immunohistochemical features of a distinct entity showing transition to dysembryoplastic neuroepithelial tumour and ganglioglioma. Neuropathol Appl Neurobiol 38(5):411–425. doi:10.1111/j.1365-2990.2011.01225.x PubMedCrossRef

14.

Boer K, Troost D, Timmerman W, Spliet WGM, van Rijen PC, Aronica E (2010) Pi3K-mTOR signaling and AMOG expression in epilepsy-associated glioneuronal tumors. Brain Pathol 20(1):234–244PubMedCrossRef

15.

Bourne TD, Schiff D (2010) Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol 6(12):695–701. doi:10.1038/nrneurol.2010.159 PubMedCrossRef

16.

Brat DJ, Scheithauer BW, Fuller GN, Tihan T (2007) Newly codified glial neoplasms of the 2007 WHO Classification of Tumours of the Central Nervous System: angiocentric glioma, pilomyxoid astrocytoma and pituicytoma. Brain Pathol 17(3):319–324 (pii:BPA082)PubMedCrossRef

17.

Buccoliero AM, Castiglione F, Degl’innocenti DR, Moncini D, Spacca B, Giordano F, Genitori L, Taddei GL (2013) Angiocentric glioma: clinical, morphological, immunohistochemical and molecular features in three pediatric cases. Clin Neuropathol 32(2):107–113. doi:10.5414/NP300500 PubMedCrossRef

18.

Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, Harter PN, Jeibmann A, von Deimling A (2011) Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol 121(2):241–252PubMedCrossRef

19.

Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20(1):245–254. doi:10.1111/j.1750-3639.2009.00352.x PubMedCrossRef

20.

Chappe C, Padovani L, Scavarda D, Forest F, Nanni-Metellus I, Loundou A, Mercurio S, Fina F, Lena G, Colin C, Figarella-Branger D (2013) Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF mutation and expression. Brain Pathol. doi:10.1111/bpa.12048 PubMed

21.

Chassoux F, Daumas-Duport C (2013) Dysembryoplastic neuroepithelial tumors: where are we now? Epilepsia 54(Suppl 9):129–134. doi:10.1111/epi.12457 PubMedCrossRef

22.

Chassoux F, Landre E, Mellerio C, Laschet J, Devaux B, Daumas-Duport C (2013) Dysembryoplastic neuroepithelial tumors: epileptogenicity related to histologic subtypes. Clin Neurophysiol 124(6):1068–1078. doi:10.1016/j.clinph.2012.11.015 PubMedCrossRef

23.

Crino PB (2011) mTOR: a pathogenic signaling pathway in developmental brain malformations. Trends Mol Med 17(12):734–742. doi:10.1016/j.molmed.2011.07.008 PubMedCrossRef

24.

Dahiya S, Haydon DH, Alvarado D, Gurnett CA, Gutmann DH, Leonard JR (2013) BRAF (V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 125(6):901–910. doi:10.1007/s00401-013-1120-y PubMedCrossRef

25.

Daumas-Duport C, Scheithauer BW, Chodkiewicz JP, Laws ER Jr, Vedrenne C (1988) Dysembryoplastic neuroepithelial tumor: a surgically curable tumor of young patients with intractable partial seizures. Report of thirty-nine cases. Neurosurgery 23(5):545–556PubMedCrossRef

26.

Dazert E, Hall MN (2011) mTOR signaling in disease. Curr Opin Cell Biol 23(6):744–755. doi:10.1016/j.ceb.2011.09.003 PubMedCrossRef

27.

de Groot M, Reijneveld JC, Aronica E, Heimans JJ (2011) Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment. Brain. doi:10.1093/brain/awr310 PubMed

28.

Deb P, Sharma MC, Tripathi M, Sarat Chandra P, Gupta A, Sarkar C (2006) Expression of CD34 as a novel marker for glioneuronal lesions associated with chronic intractable epilepsy. Neuropathol Appl Neurobiol 32(5):461–468 (pii:NAN734)PubMedCrossRef

29.

Diepholder HM, Schwechheimer K, Mohadjer M, Knoth R, Volk B (1991) A clinicopathologic and immunomorphologic study of 13 cases of ganglioglioma. Cancer 68(10):2192–2201PubMedCrossRef

30.

Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, Storm PB, Biegel JA (2010) Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro-oncology 12(7):621–630. doi:10.1093/neuonc/noq007 PubMedCentralPubMedCrossRef

31.

Duncan JS, de Tisi J (2013) MRI in the diagnosis and management of epileptomas. Epilepsia 54(Suppl 9):40–43. doi:10.1111/epi.12442 PubMedCrossRef

32.

Eisenhardt AE, Olbrich H, Roring M, Janzarik W, Anh TN, Cin H, Remke M, Witt H, Korshunov A, Pfister SM, Omran H, Brummer T (2011) Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer 129(9):2297–2303. doi:10.1002/ijc.25893 PubMedCrossRef

33.

Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, Kenney AM, Brat DJ, Perry A, Yong WH, Taylor RE, Bailey S, Clifford SC, Gilbertson RJ (2011) Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121(3):381–396PubMedCentralPubMedCrossRef

34.

Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, Zhao W, Nicholson SL, Taylor RE, Bailey S, Clifford SC (2011) Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29(11):1400–1407. doi:10.1200/JCO.2010.30.2810 PubMedCentralPubMedCrossRef

35.

Guerrini R, Rosati A, Giordano F, Genitori L, Barba C (2013) The medical and surgical treatment of tumoral seizures: current and future perspectives. Epilepsia 54(Suppl 9):84–90. doi:10.1111/epi.12450 PubMedCrossRef

36.

Hamer HM, Hong SB (2013) Is an epilepsy presurgical evaluation necessary for mid-grade and high-grade brain tumors presenting with seizures? Epilepsia 54(Suppl 9):56–60. doi:10.1111/epi.12445 PubMedCrossRef

37.

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118(4):469–474PubMedCrossRef

38.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003PubMedCrossRef

39.

Hirose T, Scheithauer BW (1998) Mixed dysembryoplastic neuroepithelial tumor and ganglioglioma. Acta Neuropathol 95(6):649–654PubMedCrossRef

40.

Hoischen A, Ehrler M, Fassunke J, Simon M, Baudis M, Landwehr C, Radlwimmer B, Lichter P, Schramm J, Becker AJ, Weber RG (2008) Comprehensive characterization of genomic aberrations in gangliogliomas by CGH, array-based CGH and interphase FISH. Brain Pathol 18(3):326–337 BPA122 [pii]PubMedCrossRef

41.

Honavar M, Janota I, Polkey CE (1999) Histological heterogeneity of dysembryoplastic neuroepithelial tumour: identification and differential diagnosis in a series of 74 cases. Histopathology 34(4):342–356PubMedCrossRef

42.

Japp A, Gielen GH, Becker AJ (2013) Recent aspects of classification and epidemiology of epilepsy-associated tumors. Epilepsia 54(Suppl 9):5–11. doi:10.1111/epi.12436 PubMedCrossRef

43.

Kennedy J, Schuele SU (2013) Long-term monitoring of brain tumors: when is it necessary? Epilepsia 54(Suppl 9):50–55. doi:10.1111/epi.12444 PubMedCrossRef

44.

Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Vital A, Mariani L, Stawski R, Watanabe T, De Girolami U, Kleihues P, Ohgaki H (2010) Molecular classification of low-grade diffuse gliomas. Am J Pathol 177(6):2708–2714. doi:10.2353/ajpath.2010.100680 PubMedCentralPubMedCrossRef

45.

Koelsche C, Wohrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M, Lasitschka F, von Deimling A, Capper D (2013) Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol. doi:10.1007/s00401-013-1100-2 PubMedCentral

46.

Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C (2009) Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118(3):401–405. doi:10.1007/s00401-009-0550-z PubMedCrossRef

47.

Lellouch-Tubiana A, Boddaert N, Bourgeois M, Fohlen M, Jouvet A, Delalande O, Seidenwurm D, Brunelle F, Sainte-Rose C (2005) Angiocentric neuroepithelial tumor (ANET): a new epilepsy-related clinicopathological entity with distinctive MRI. Brain Pathol 15(4):281–286PubMedCrossRef

48.

Lhatoo SD, Moghimi N, Schuele S (2013) Tumor-related epilepsy and epilepsy surgery. Epilepsia 54(Suppl 9):1–4. doi:10.1111/epi.12435 PubMedCrossRef

49.

Lim KC, Crino PB (2013) Focal malformations of cortical development: new vistas for molecular pathogenesis. Neuroscience 252:262–276PubMedCrossRef

50.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO Classification of Tumours of the Central Nervous System. In: World Health Organization Classification of Tumours. IARC, Lyon

51.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109. doi:10.1007/s00401-007-0243-4 PubMedCentralPubMedCrossRef

52.

Luyken C, Blumcke I, Fimmers R, Urbach H, Elger CE, Wiestler OD, Schramm J (2003) The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia 44(6):822–830PubMedCrossRef

53.

Luyken C, Blumcke I, Fimmers R, Urbach H, Wiestler OD, Schramm J (2004) Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer 101(1):146–155PubMedCrossRef

54.

Majores M, von Lehe M, Fassunke J, Schramm J, Becker AJ, Simon M (2008) Tumor recurrence and malignant progression of gangliogliomas. Cancer 113(12):3355–3363. doi:10.1002/cncr.23965 PubMedCrossRef

55.

Marburger T, Prayson R (2011) Angiocentric glioma: a clinicopathologic review of 5 tumors with identification of associated cortical dysplasia. Arch Pathol Lab Med 135(8):1037–1041. doi:10.5858/2010-0668-OAR PubMedCrossRef

56.

Miyata H, Ryufuku M, Kubota Y, Ochiai T, Niimura K, Hori T (2012) Adult-onset angiocentric glioma of epithelioid cell-predominant type of the mesial temporal lobe suggestive of a rare but distinct clinicopathological subset within a spectrum of angiocentric cortical ependymal tumors. Neuropathology 32(5):479–491. doi:10.1111/j.1440-1789.2011.01278.x PubMedCrossRef

57.

Ostrom Q, Cohen ML, Ondracek A, Sloan A, Barnholtz-Sloan J (2013) Gene markers in brain tumors: what the epileptologist should know. Epilepsia 54(Suppl 9):25–29. doi:10.1111/epi.12439 PubMedCrossRef

58.

Palmini A, Paglioli E, Silva VD (2013) Developmental tumors and adjacent cortical dysplasia: single or dual pathology? Epilepsia 54(Suppl 9):18–24. doi:10.1111/epi.12438 PubMedCrossRef

59.

Parry L, Maynard JH, Patel A, Hodges AK, von Deimling A, Sampson JR, Cheadle JP (2000) Molecular analysis of the TSC1 and TSC2 tumour suppressor genes in sporadic glial and glioneuronal tumours. Hum Genet 107(4):350–356PubMedCrossRef

60.

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812. doi:10.1126/science.1164382 PubMedCentralPubMedCrossRef

61.

Pasquier B, Peoc HM, Fabre-Bocquentin B, Bensaadi L, Pasquier D, Hoffmann D, Kahane P, Tassi L, Le Bas JF, Benabid AL (2002) Surgical pathology of drug-resistant partial epilepsy. A 10-year-experience with a series of 327 consecutive resections. Epileptic Disord 4(2):99–119PubMed

62.

Perry A, Giannini C, Scheithauer BW, Rojiani AM, Yachnis AT, Seo IS, Johnson PC, Kho J, Shapiro S (1997) Composite pleomorphic xanthoastrocytoma and ganglioglioma: report of four cases and review of the literature. Am J Surg Pathol 21(7):763–771PubMedCrossRef

63.

Perucca E (2013) Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia 54(Suppl 9):97–104. doi:10.1111/epi.12452 PubMedCrossRef

64.

Piao YS, Lu DH, Chen L, Liu J, Wang W, Liu L, Yu T, Wang YP, Li YJ (2010) Neuropathological findings in intractable epilepsy: 435 Chinese cases. Brain Pathol 20(5):902–908. doi:10.1111/j.1750-3639.2010.00386.x PubMed

65.

Prabowo AS, Iyer AM, Veersema TJ, Anink JJ, Schouten-van Meeteren AY, Spliet WG, van Rijen PC, Ferrier CH, Capper D, Thom M, Aronica E (2014) BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors. Brain Pathol 24(1):52–66. doi:10.1111/bpa.12081 PubMedCrossRef

66.

Prayson RA (2011) Brain tumors in adults with medically intractable epilepsy. Am J Clin Pathol 136(4):557–563. doi:10.1309/AJCP0RBUQAQPZOUE PubMedCrossRef

67.

Prayson RA, Napekoski KM (2012) Composite ganglioglioma/dysembryoplastic neuroepithelial tumor: a clinicopathologic study of 8 cases. Hum Pathol 43(7):1113–1118. doi:10.1016/j.humpath.2011.08.023 PubMedCrossRef

68.

Preusser M, Hoischen A, Novak K, Czech T, Prayer D, Hainfellner JA, Baumgartner C, Woermann FG, Tuxhorn IE, Pannek HW, Bergmann M, Radlwimmer B, Villagran R, Weber RG, Hans VH (2007) Angiocentric glioma: report of clinico-pathologic and genetic findings in 8 cases. Am J Surg Pathol 31(11):1709–1718. doi:10.1097/PAS.0b013e31804a7ebb PubMedCrossRef

69.

Raghunathan A, Olar A, Vogel H, Parker JR, Coventry SC, Debski R, Albarracin CT, Aldape KD, Cahill DP 3rd, Powell SZ, Fuller GN (2012) Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. Ann Diagn Pathol 16(4):255–259. doi:10.1016/j.anndiagpath.2011.11.003 PubMedCrossRef

70.

Rajneesh KF, Binder DK (2009) Tumor-associated epilepsy. Neurosurg Focus 27(2):E4PubMedCrossRef

71.

Ramkissoon LA, Horowitz PM, Craig JM, Ramkissoon SH, Rich BE, Schumacher SE, McKenna A, Lawrence MS, Bergthold G, Brastianos PK, Tabak B, Ducar MD, Van Hummelen P, MacConaill LE, Pouissant-Young T, Cho YJ, Taha H, Mahmoud M, Bowers DC, Margraf L, Tabori U, Hawkins C, Packer RJ, Hill DA, Pomeroy SL, Eberhart CG, Dunn IF, Goumnerova L, Getz G, Chan JA, Santagata S, Hahn WC, Stiles CD, Ligon AH, Kieran MW, Beroukhim R, Ligon KL (2013) Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci USA 110(20):8188–8193. doi:10.1073/pnas.1300252110 PubMedCentralPubMedCrossRef

72.

Ray WZ, Blackburn SL, Casavilca-Zambrano S, Barrionuevo C, Orrego JE, Heinicke H, Dowling JL, Perry A (2009) Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: a report of 5 cases and review of the literature. J Neurooncol 94(2):283–292PubMedCrossRef

73.

Reifenberger G, Kaulich K, Wiestler OD, Blumcke I (2003) Expression of the CD34 antigen in pleomorphic xanthoastrocytomas. Acta Neuropathol 105(4):358–364PubMed

74.

Rodriguez FJ, Giannini C (2010) Oligodendroglial tumors: diagnostic and molecular pathology. Semin Diagn Pathol 27(2):136–145PubMedCrossRef

75.

Rogers LR (2013) Chemotherapy and immunotherapy of brain tumors: what the epileptologist must know. Epilepsia 54(Suppl 9):105–108. doi:10.1111/epi.12453 PubMedCrossRef

76.

Romeike BF, Mawrin C (2009) MAP-2 immunoexpression in gliomatosis cerebri. Histopathology 54(4):504–505. doi:10.1111/j.1365-2559.2009.03236.x PubMedCrossRef

77.

Rosenow F, Menzler K (2013) Invasive EEG studies in tumor-related epilepsy: when are they indicated and with what kind of electrodes? Epilepsia 54(Suppl 9):61–65PubMedCrossRef

78.

Samadani U, Judkins AR, Akpalu A, Aronica E, Crino PB (2007) Differential cellular gene expression in ganglioglioma. Epilepsia 48(4):646–653PubMedCrossRef

79.

Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397–405PubMedCrossRef

80.

Schramm J, Luyken C, Urbach H, Fimmers R, Blumcke I (2004) Evidence for a clinically distinct new subtype of grade II astrocytomas in patients with long-term epilepsy. Neurosurgery 55(2):340–347 (discussion 347–348)PubMedCrossRef

81.

Schwalbe EC, Lindsey JC, Straughton D, Hogg TL, Cole M, Megahed H, Ryan SL, Lusher ME, Taylor MD, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC (2011) Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res 17(7):1883–1894. doi:10.1158/1078-0432.CCR-10-2210 PubMedCentralPubMedCrossRef

82.

Shafit-Zagardo B, Davies P, Rockwood J, Kress Y, Lee SC (2000) Novel microtubule-associated protein-2 isoform is expressed early in human oligodendrocyte maturation. Glia 29(3):233–245PubMedCrossRef

83.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330 PubMedCrossRef

84.

Sung CO, Suh YL, Hong SC (2011) CD34 and microtubule-associated protein 2 expression in dysembryoplastic neuroepithelial tumours with an emphasis on dual expression in non-specific types. Histopathology 59(2):308–317. doi:10.1111/j.1365-2559.2011.03936.x PubMed

85.

Suzuki SO, Kitai R, Llena J, Lee SC, Goldman JE, Shafit-Zagardo B (2002) MAP-2e, a novel MAP-2 isoform, is expressed in gliomas and delineates tumor architecture and patterns of infiltration. J Neuropathol Exp Neurol 61(5):403–412PubMed

86.

Tandon N, Esquenazi Y (2013) Resection strategies in tumoral epilepsy: is a lesionectomy enough? Epilepsia 54(Suppl 9):72–78. doi:10.1111/epi.12448 PubMedCrossRef

87.

Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123(4):465–472. doi:10.1007/s00401-011-0922-z PubMedCentralPubMedCrossRef

88.

Thom M, Blumcke I, Aronica E (2012) Long-term epilepsy-associated tumors. Brain Pathol 22(3):350–379. doi:10.1111/j.1750-3639.2012.00582.x PubMedCrossRef

89.

Thom M, Toma A, An S, Martinian L, Hadjivassiliou G, Ratilal B, Dean A, McEvoy A, Sisodiya SM, Brandner S (2011) One hundred and one dysembryoplastic neuroepithelial tumors: an adult epilepsy series with immunohistochemical, molecular genetic, and clinical correlations and a review of the literature. J Neuropathol Exp Neurol 70(10):859–878. doi:10.1097/NEN.0b013e3182302475 PubMedCrossRef

90.

van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6(5):421–430PubMedCrossRef

91.

Wang M, Tihan T, Rojiani AM, Bodhireddy SR, Prayson RA, Iacuone JJ, Alles AJ, Donahue DJ, Hessler RB, Kim JH, Haas M, Rosenblum MK, Burger PC (2005) Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol 64(10):875–881PubMedCrossRef

92.

Wiebe S, Blume WT, Girvin JP, Eliasziw M (2001) A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 345(5):311–318PubMedCrossRef

93.

Wolf HK, Buslei R, Schmidt Kastner R, Schmidt Kastner PK, Pietsch T, Wiestler OD, Blumcke I (1996) NeuN: a useful neuronal marker for diagnostic histopathology. J Histochem Cytochem 44(10):1167–1171PubMedCrossRef

94.

Wolf HK, Wiestler OD (1993) Surgical pathology of chronic epileptic seizure disorders. Brain Pathol 3:371–380PubMedCrossRef

95.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773. doi:10.1056/NEJMoa0808710 PubMedCentralPubMedCrossRef

96.

Zemke D, Azhar S, Majid A (2007) The mTOR pathway as a potential target for the development of therapies against neurological disease. Drug News Perspect 20(8):495–499. doi:10.1358/dnp.2007.20.8.1157618 PubMedCrossRef

97.

Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I, Boop FA, Lu C, Kandoth C, Ding L, Lee R, Huether R, Chen X, Hedlund E, Nagahawatte P, Rusch M, Boggs K, Cheng J, Becksfort J, Ma J, Song G, Li Y, Wei L, Wang J, Shurtleff S, Easton J, Zhao D, Fulton RS, Fulton LL, Dooling DJ, Vadodaria B, Mulder HL, Tang C, Ochoa K, Mullighan CG, Gajjar A, Kriwacki R, Sheer D, Gilbertson RJ, Mardis ER, Wilson RK, Downing JR, Baker SJ, Ellison DW (2013) Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45(6):602–612. doi:10.1038/ng.2611 PubMedCentralPubMedCrossRef

Title: A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors
Authors: Ingmar Blumcke
Eleonora Aronica
Horst Urbach
Andreas Alexopoulos
Jorge A. Gonzalez-Martinez
Publication date: 01-07-2014
Publisher: Springer Berlin Heidelberg
Published in: Acta Neuropathologica / Issue 1/2014
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-014-1288-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Tau protein mutation P364S in two sisters: clinical course and neuropathology with emphasis on new, composite neuronal tau inclusions

Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts

Improved health-related quality of life outcomes associated with SHH subgroup medulloblastoma in SIOP-UKCCSG PNET3 trial survivors

Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology

Cerebral cavernous malformations in the setting of focal epilepsies: pathological findings, clinical characteristics, and surgical treatment principles

Pathology-based approach to epilepsy surgery